These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
860 related articles for article (PubMed ID: 16552239)
1. Evaluation, prevention and management of radiotherapy-induced xerostomia in head and neck cancer patients. de Castro G; Federico MH Curr Opin Oncol; 2006 May; 18(3):266-70. PubMed ID: 16552239 [TBL] [Abstract][Full Text] [Related]
2. Toxicity and compliance of subcutaneous amifostine in patients undergoing postoperative intensity-modulated radiation therapy for head and neck cancer. Thorstad WL; Chao KS; Haughey B Semin Oncol; 2004 Dec; 31(6 Suppl 18):8-12. PubMed ID: 15726516 [TBL] [Abstract][Full Text] [Related]
3. Pathophysiology and management of radiation-induced xerostomia. Berk LB; Shivnani AT; Small W J Support Oncol; 2005; 3(3):191-200. PubMed ID: 15915820 [TBL] [Abstract][Full Text] [Related]
4. The role of saliva in oral health: strategies for prevention and management of xerostomia. Brosky ME J Support Oncol; 2007 May; 5(5):215-25. PubMed ID: 17564151 [TBL] [Abstract][Full Text] [Related]
5. New approaches to preventing xerostomia. J Support Oncol; 2006 Feb; 4(2):87-8. PubMed ID: 16499130 [No Abstract] [Full Text] [Related]
6. Management of salivary hypofunction during and after radiotherapy. Shiboski CH; Hodgson TA; Ship JA; Schiødt M Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2007 Mar; 103 Suppl():S66.e1-19. PubMed ID: 17379158 [TBL] [Abstract][Full Text] [Related]
8. A phase II study to assess the efficacy of amifostine for submandibular/sublingual salivary sparing during the treatment of head and neck cancer with intensity modulated radiation therapy for parotid salivary sparing. Rosenthal DI; Chambers MS; Weber RS; Eisbruch A Semin Oncol; 2004 Dec; 31(6 Suppl 18):25-8. PubMed ID: 15726519 [TBL] [Abstract][Full Text] [Related]
9. Effect of Amifostine to prevent radiotherapy-induced acute and late toxicity in head and neck cancer patients who had normal or mild impaired salivary gland function. Veerasarn V; Phromratanapongse P; Suntornpong N; Lorvidhaya V; Sukthomya V; Chitapanarux I; Tesavibul C; Swangsilpa T; Khorprasert C; Shotelersuk K; Kongthanarat Y; Panichevaluk A; Chiewvit S; Pusuwan P; Aekmahachai M; Ratchadara S; Sirilipoche S; Saengsuda Y J Med Assoc Thai; 2006 Dec; 89(12):2056-67. PubMed ID: 17214057 [TBL] [Abstract][Full Text] [Related]
10. Radioprotective effect of amifostine in patients with head and neck squamous cell carcinoma. Bourhis J; Rosine D Semin Oncol; 2002 Dec; 29(6 Suppl 19):61-2. PubMed ID: 12577247 [TBL] [Abstract][Full Text] [Related]
11. [Current status of prevention and management of radiation-induced xerostomia]. Ma DY; Qiu WL; Zhang CP Zhonghua Kou Qiang Yi Xue Za Zhi; 2010 Feb; 45(2):121-3. PubMed ID: 20368009 [No Abstract] [Full Text] [Related]
12. Radiation-induced xerostomia in patients with head and neck cancer: pathogenesis, impact on quality of life, and management. Chambers MS; Garden AS; Kies MS; Martin JW Head Neck; 2004 Sep; 26(9):796-807. PubMed ID: 15350026 [TBL] [Abstract][Full Text] [Related]
13. Serious adverse effects of amifostine during radiotherapy in head and neck cancer patients. Rades D; Fehlauer F; Bajrovic A; Mahlmann B; Richter E; Alberti W Radiother Oncol; 2004 Mar; 70(3):261-4. PubMed ID: 15064010 [TBL] [Abstract][Full Text] [Related]
14. A randomized study to assess the effectiveness of orally administered pilocarpine during and after radiotherapy of head and neck cancer. Nyárády Z; Németh A; Bán A; Mukics A; Nyárády J; Ember I; Olasz L Anticancer Res; 2006; 26(2B):1557-62. PubMed ID: 16619571 [TBL] [Abstract][Full Text] [Related]
15. [Side effects of postoperative radiochemotherapy with amifostine versus radiochemotherapy alone in head and neck tumors. Preliminary results of a prospective randomized trial]. Vacha P; Marx M; Engel A; Richter E; Feyerabend T Strahlenther Onkol; 1999 Nov; 175 Suppl 4():18-22. PubMed ID: 10584135 [TBL] [Abstract][Full Text] [Related]
16. Amifostine reduces radiation therapy-induced dry mouth in head and neck cancer patients. Oncology (Williston Park); 2004 Sep; 18(10):1314, 1316. PubMed ID: 15526835 [No Abstract] [Full Text] [Related]
17. Influence of intravenous amifostine on xerostomia, tumor control, and survival after radiotherapy for head-and- neck cancer: 2-year follow-up of a prospective, randomized, phase III trial. Wasserman TH; Brizel DM; Henke M; Monnier A; Eschwege F; Sauer R; Strnad V Int J Radiat Oncol Biol Phys; 2005 Nov; 63(4):985-90. PubMed ID: 16253773 [TBL] [Abstract][Full Text] [Related]
18. Effect of pilocarpine during radiation therapy: results of RTOG 97-09, a phase III randomized study in head and neck cancer patients. Scarantino C; LeVeque F; Swann RS; White R; Schulsinger A; Hodson DI; Meredith R; Foote R; Brachman D; Lee N J Support Oncol; 2006 May; 4(5):252-8. PubMed ID: 16724649 [TBL] [Abstract][Full Text] [Related]
19. Salivary gland sparing in the treatment of head and neck cancer. Scrimger R Expert Rev Anticancer Ther; 2011 Sep; 11(9):1437-48. PubMed ID: 21929317 [TBL] [Abstract][Full Text] [Related]